Pancreatic cancer cells in a dish normally crawl. These ones stopped. In experiments at Florida A&M University, one experimental compound halted over 90 percent of the cells’ movement at only 1 µM, and the researchers say that points to a possible brake on how the disease spreads.
KRAS is the gene behind it. Mutations in KRAS push most pancreatic ductal adenocarcinoma tumors to divide fast, and the gene has long carried the label “undruggable.” Current drugs lose their punch because tumors become resistant. In their paper in Oncotarget, the authors wrote: “The limited number of drugs to treat KRAS-driven cancers remains a significant healthcare problem, with the current drugs becoming ineffective due to intrinsic resistance.”
A different target
A team from the university’s pharmacy college in Tallahassee works on polyisoprenylated cysteinyl amide inhibitors, known as PCAIs. Instead of going after one particular KRAS mutation, these compounds were designed to disrupt the abnormal protein interactions that mutant KRAS depends on. Kweku Ofosu-Asante is first author, Nazarius S. Lamango the corresponding author, and the paper appeared on June 3, 2026.
Two of the compounds stood out. The lead candidate, NSL-YHJ-2-27, cut cell viability sharply and strongly curbed migration. Under the microscope the cells changed shape, rounding up as their actin filaments, the internal scaffolding they use to move and invade tissue, broke down. The treatment also cut the amount of G-proteins that drive cell movement and shifted the activity of genes tied to tumor progression.
An unexpected twist
Here the result turned odd. The researchers expected the compounds to quiet the main growth-signaling pathways downstream of KRAS. They did the opposite. MAPK and PI3K/AKT, the two big pathways, went into overdrive, which produced a surge of reactive oxygen species and set off apoptosis, the cell’s built-in self-destruct routine. Why overload kills these cells is not yet understood, and the authors say more work is needed.
The effect held up in three-dimensional tumor spheroids, which are closer to real tumors than a flat layer of cells. The spheroids fell apart, invaded less of the surrounding matrix and showed a higher share of dying cells.
The authors argue the compounds act against several KRAS variants, naming G12C, G12D and G12V. “Indeed, our previous works revealed the effectiveness of the PCAIs against breast, lung, and prostate cancer cells driven by mutant KRAS proteins,” they wrote. Roughly 30 percent of solid-tumor cancers, colorectal and lung among them, involve KRAS.
Still a long way off
Everything so far happened in lab-grown cells. Nobody yet knows whether the compounds harm healthy tissue or whether they work and stay safe in animal models, a step that has to come before any human trial. Their summary of what the data suggest is cautious but pointed: “therapies that abrogate tumor cell motility have a strong potential to positively impact cancer management.”
Sources
- Experimental compounds trigger cancer cell death in KRAS-driven pancreatic cancer
- Drug Stops 90% of Pancreatic Cancer Migration in Lab Tests
